RSS

Aprea Therapeutics

Aprea Therapeutics, Karolinska Development’s portfolio company, has announced a collaboration with Memorial Sloan Kettering Cancer Center to study the effects of reactivation of tumour suppressor protein p53 by APR-246. more

News